* Indications:
# Primary Hypercholesterolemia:
– EZETROL, administered with an HMG-CoA reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for
the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B),
and triglycerides (TG) and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous
familial and non-familial) hypercholesterolemia.
– EZETROL, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated
total-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia.
# Homozygous Familial Hypercholesterolemia (HoFH): EZETROL, administered with a statin, is indicated for the reduction of
elevated total-C and LDL-C levels in patients with HoFH. Patients may also receive adjuctive treatments (e.g., LDL apheresis).
# Homozygous Sitosterolemia (Phytosterolemia): EZETROL is indicated for the reduction of elevated sitosterol & campesterol
levels in patients with homozygous familial sitosterolemia.
* Dosage and Administration:
– The patient should be placed on an appropriate lipid-lowering diet and should continue on this diet during treatment with EZETROL.
– The recommended dose of EZETROL is 10mg once daily, used alone, with a statin, or with fenofibrate. EZETROL can be
administered at any time of the day, with or without food.
– Use in the Elderly: No dosage adjustment is required for elderly patients.
– Use in Pediatric Patients: Children and adolescents >/= 10 years: No dosage adjustment is required.
Children < 10 years: treatment with EZETROL is not recommended.
– Use in Hepatic Impairment: No dosage adjustment is required in patients with mild hepatic insufficiency (Child-Pugh score 5 to 6).
Treatment with ezetimibe is not recommended in patients with moderate (Child-Pugh score 7 to 9)
or severe (Child-Pugh score > 9) liver dysfunction.
– Use in Renal Impairment: No dosage adjustment is required for renally impaired patients:
– Co-administration with bile acid sequestrants: Dosing of EZETROL should occur either >/= 2 hours before or >/= 4 hours
after administration of a bile acid sequestrant.
* Store in a dry place at temperature between 15 – 30 degrees C. Protected from moisture & light.
Do not store above 30 degrees C (86 degrees F). Store in the original package.
* Manufactured by: Schering Plough Products Inc. – Puerto Rico.
Packed by: Global Napi Pharmaceuticals (GNP) – Egypt.
For: MSD – SP Limited – U.K. (MA Holder)
For: Merck Sharp & Dohme – U.K.
Weight | 100 kg |
---|
Add a review
You must be logged in to post a review
Log In
Q & A
There are no questions yet
Ask a question
Your question will be answered by a store representative or other customers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the question!
Your question has been received and will be answered soon. Please do not submit the same question again.
Error
An error occurred when saving your question. Please report it to the website administrator. Additional information:
Add an answer
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the answer!
Your answer has been received and will be published soon. Please do not submit the same answer again.
Error
An error occurred when saving your answer. Please report it to the website administrator. Additional information:
Reviews
There are no reviews yet